NCT02521610View on ClinicalTrials.gov

A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Healthy Volunteer
Interventions
DRUG

Placebo

Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.

DRUG

RG7625

Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.

Trial Locations (1)

9471 GP

Zuidlaren

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02521610 - A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers | Biotech Hunter | Biotech Hunter